Humana (HUM)
(Delayed Data from NYSE)
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$279.45 USD
-37.29 (-11.77%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $278.50 -0.95 (-0.34%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth F Momentum D VGM
Zacks News
Higher Optum Revenues to Drive UnitedHealth (UNH) Q4 Earnings
by Zacks Equity Research
Increased contribution across Optum's segments should support UnitedHealth's (UNH) earnings in Q4.
Top Research Reports for Wal-Mart, 3M & Union Pacific
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Wal-Mart (WMT), 3M (MMM) and Union Pacific (UNP).
Humana Extends Contract With Tivity Health, Spurs Healthcare
by Zacks Equity Research
Humana (HUM) continues to form strategic partnerships to improve the overall health of its Medicare Advantage members.
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Anthem, Humana, Centene, Molina Healthcare and Joint
3 Outperformers from Health Insurance in 2017
by Zacks Equity Research
The health insurance industry has witnessed regulatory uncertainties around Affordable Care Act, public exchange losses and inorganic growth in 2017.
Can Walgreens' Retail Pharmacy USA Segment Drive Q1 Earnings?
by Zacks Equity Research
Walgreens Boots (WBA) rides high on strength in Retail Pharmacy USA division in fiscal 2017.
Anthem Buys HealthSun to Expand Medicare Business in Florida
by Zacks Equity Research
Anthem's (ANTM) buyout of HealthSun reflects its long-term strategy to grow in the Medicare Advantage business.
Humana-Kindred Deal Keeps Shakeout Alive in Healthcare Space
by Zacks Equity Research
Humana's (HUM) agreement to acquire Kindred at Home aligns with its strategy to grow vertically.
PBM Industry Shows Strength: 3 Stocks in Focus
by Zacks Equity Research
Consider these three stocks for grand returns from the high-potential PBM market.
CVS-Aetna Deal: What's Hot, What's Not
by Zacks Equity Research
CVS Health (CVS) and Aetna consolidation to add a new dimension to healthcare landscape. However, critics believe the gain will be short-lived for the healthcare society.
Humana Partners Einstein Healthcare for Value-Based Care
by Zacks Equity Research
Humana (HUM) has been joining forces with other medical sector companies in order to strengthen its presence in value-based healthcare.
Humana's Medicare Business Impresses, Public Exchange Hurts
by Zacks Equity Research
Although Humana (HUM) continues to grow on the back of Medicare and Medicaid expansions, threats from its exchange business weigh on both revenues and margins.
Can Health Insurers Continue to Look Past ACA Threats in Q4?
by Zacks Equity Research
Despite regulatory challenges, health insurance companies have the potential to outperform in Q4 on growing demand for government plans, reduced uninsured rates and aging U.S. population.
Anthem (ANTM) Grows on Membership, Rising Expenses Hurt
by Zacks Equity Research
Anthem's (ANTM) revenues gain from solid membership base and rising net investment income. However, public exchange loss and rising expenses continue to bother.
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TOTAL S.A., Humana, Novo Nordisk, Target and Xcel
Ensign Group (ENSG) Q3 Earnings Miss Estimates, Rise Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) earnings missed estimates in Q3 but grew year over year due to higher revenues.
Humana (HUM) Beats Q3 Earnings Estimates, Revenues Miss
by Zacks Equity Research
Humana's (HUM) strong third-quarter earnings were driven by significantly low share count.
Humana's (HUM) Q3 Earnings Beat, Revenues Miss
by Anupama Mukhopadhyay
Humana's (HUM) third quarter earnings beat estimates but revenues miss expectations.
Can Retail Segment Further Drive Humana's (HUM) Q3 Earnings?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to be driven by strong performance of its Retail segment.
Cigna (CI) Q3 Earnings Beat on Higher Enrollment, Guides Up
by Zacks Equity Research
Cigna's (CI) strong third-quarter earnings were driven by broad-based growth across its business segments.
Will Increased Visits Drive Teladoc's (TDOC) Q3 Earnings?
by Zacks Equity Research
Teladoc's (TDOC) earnings will benefit from its premier consumer engagement capabilities, broad network and scalable platform, which will increase visits and clients.
Will High Costs Dent Envision Healthcare (EVHC) Q3 Earnings?
by Zacks Equity Research
Envision Healthcare's (EVHC) third-quarter earnings are likely to see a drag from high expenses, partly offset by increased revenues from its physician services segment.
Will Lower Health Care Revenues Mar Aetna (AET) Q3 Earnings?
by Zacks Equity Research
Aetna's (AET) third-quarter earnings are likely see a drain from lesser membership and low revenues in the Health Care segment, partly offset by benefits from share buyback and cost control.
Will Higher Admissions Aid HCA Healthcare (HCA) Q3 Earnings?
by Zacks Equity Research
HCA Healthcare's (HCA) third-quarter earnings are likely to be benefited by its inorganic growth measures partly offset by industry weakness.
Can Admissions Rise Fuel Universal Health (UHS) Q3 Earnings?
by Zacks Equity Research
Universal Health's (UHS) third-quarter results are likely to be driven by solid revenue growth in both its Acute Care and Behavioral Health segments.